A drug that blocks a key protein in the body's cells that rhinoviruses use to self-replicate could cure the common cold, according to a study published in Nature Chemistry, and human clinical trials on the compound could get underway within two years. The compound worked quickly in lab experiments on human lung cells, the researchers reported.
Targeting the host rather than the virus could kill the common cold
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.